Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports from Herlev University highlight recent research in breast cancer
May 15th, 2008
According to a study from Herlev, Denmark, " CHEK2* 1100delC heterozygosity may be associated with an increased risk of breast cancer; however, it is unclear whether the evidence is sufficient to recommend genotyping in clinical practice. Patients and Methods We identified studies on CHEK2* 1100delC heterozygosity and the risk of unselected, early-onset, and familial breast cancer through comprehensive, computer-based searches of PubMed, EMBASE, and Web of Science." "Aggregated risk estimates were compared with previous estimates for BRCA1 and BRCA2 mutation heterozygotes. By using fixed-effect models for CHEK2* 1100delC heterozygotes versus noncarriers, we found...
Source: Women's Health Weekly (2008-05-15)
|
